Assort Health raises $120M Series C to scale its voice AI platform

Assort Health has raised a $120 million Series C led by Menlo Ventures at a $1.2 billion valuation. The voice AI platform for healthcare patient access has now raised $222 million since launching in November 2023, with $146 million of that in the seven months since its $76 million Series B. Lightspeed, Felicis, First Round, Chemistry, Joe Montana, Tau Ventures, and Quiet Capital joined. JP Sanday of Menlo is taking a board seat.

The pitch is a platform thesis applied to one of the most expensive administrative backlogs in the economy. Healthcare providers in the US spend nearly twice as much on administration as on direct patient care, a $1.1 trillion annual burden, and most of that overhead is concentrated in the same handful of patient-facing workflows: scheduling, intake, referrals, medication refills, eligibility checks, and payments. Assort's bet is that owning the front door of those workflows with a unified AI agent platform, rather than a constellation of single-purpose bots, is the only way to drive automation rates high enough to matter at scale.

The specialty dataset Assort Health is building

What separates Assort from a long list of well-funded competitors is its proprietary specialty dataset, built on 190 million patient interactions, 62,000 care protocols, and 1.6 million decision pathways across more than 20 specialties. That dataset is the training material for Synapse, Assort's proprietary AI model that learns the patterns of specialty workflows across every deployment, then generates the edge cases, tests, and simulations each one has to handle. Each new customer adds more data, and the platform gets sharper for the next customer, automatically.

That compounding loop is the structural advantage Menlo is paying for. "The value of Assort's platform compounds with every patient interaction. Each one surfaces a new edge case and a new way to improve care, and the platform gets better for the next patient, automatically. That is a structural advantage that grows with scale, and it lets Assort deliver outsized value for every customer in a way other platforms simply haven't matched," said Matt Murphy, partner at Menlo Ventures. Murphy's partner JP Sanday, who is joining the board, framed the bet in industry terms: "Every so often a company comes along that fundamentally reimagines how an industry operates. Assort is that company for healthcare."

The customer base tells the same story. Customers see a 5% lift in appointment volume, a 115% increase in labor capacity, and a 4.3 out of 5 patient satisfaction score, the company said. MDCS Dermatology, a 9-location practice that sees 130,000 to 138,000 patient visits a year, evaluated every AI solution on the market before picking Assort. "Assort was the only true platform. It runs the full patient journey as one connected system, from referrals and document processing to intake, care gap closure, real-time eligibility, and payments," said Dr. Parinita Amin, CEO of MDCS Dermatology. "The difference is memory. Everyone else automates one piece and forgets the rest. Assort remembers every patient across every interaction and connects it all into one conversation."

Why voice agents are winning the front door

The product surface has expanded well beyond scheduling. Concierge, Assort's inbound voice agent, now handles triage, lab requests, medication refills, insurance eligibility, and intake in any language. Activate is the outbound agent, closing referral loops, automatically acting on detected care gaps such as mammograms, colonoscopies, and vaccines, recovering no-shows, and resolving payments. Orchestrate runs the operational work behind each visit and writes every detail back to the electronic health record, including referrals, document processing, and personalized pre- and post-visit forms. A separate staff copilot module gives front-office teams a real-time assistant for complex patient access work. All four are connected by Patient Journey Memory, a continuous record for each patient that carries context across every channel.

Voice is the channel that is winning. Healthcare voice-AI startups are seeing revenue ramp faster than text or chat agents, and the category is now large enough to draw dedicated venture capital. Artera secured $65 million in December for AI agents in patient communications. EliseAI picked up $250 million in a Series E in August. Hello Patient, Tennr, and Prosper AI are all on similar trajectories, with Prosper banking $30 million this week. The pitch for voice-first is the same one Assort co-CEO Jon Wang has been making for two years: phone calls remain the single largest patient access surface in the country, and a mishandled call means losing the patient. "When a patient reaches out for care, you often get one chance to earn their trust. A mishandled interaction doesn't just create operational problems; it can mean losing that patient altogether," said Jon Shaker, executive director of the Boston Bone and Joint Institute. The agentic voice test-and-eval layer, where startups like Coval are building pre-deployment simulation, is one sign that the category is taking its quality bar seriously. Coval's recent $28M raise for voice-agent testing is a useful parallel to watch.

The Synapse model and the $120M round

The new capital is going to fund three concrete pushes. The first is a major expansion into health system operations. Assort is now deploying behind the largest AI-powered patient access deployment among provider groups, and several health systems, including John Muir Health, are partnering with the company to support complex ambulatory operations at scale. The second is continued investment in Synapse, which Wang calls the foundation that lets Assort "build faster than anyone in the market." Co-CEO Jeffery Liu added that the proprietary model is what allows Assort to move past answering calls toward automating the entire patient journey. The third is geographic and specialty expansion. Assort is deepening coverage in the 20-plus specialties it already serves, from orthopedics and dermatology to cardiology, gastroenterology, and women's health, while pushing into the long tail of provider groups and community health centers that have been waiting for a platform that can handle their complexity.

Wang expects consolidation. "Provider groups know it, and the smart ones aren't buying another point solution. They want one partner with the capital and the engineering depth to transform how they operate over the long run," he said. The Series C gives Assort that depth. The company has $222 million in cumulative funding, a 20x revenue ramp in 15 months, and what Wang describes as proprietary data that Anthropic and OpenAI do not have. Whether that is enough to win the multi-decade rebuild of healthcare patient access is the open question, but the company is now capitalized to keep trying. For a look at how agent platforms are reshaping enterprise back-office workflows beyond healthcare, the best AI coding agents in 2026 reference page tracks the parallel shift in software engineering. The full deal is detailed in Assort Health's own announcement of the round.